RMC-6272 (RM-006) is a bi-steric mTORC1 -selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 tumors. In Vitro RMC-6272 shows more effective growth inhibition in multiple TSC1 or TSC2 mutant tumor cell lines compared to Rapamycin. RMC-6272 causes a more profound growth inhibition in the TSC1 or TSC2 mutant cells than the wild type cells. RMC-6272 at ~1 nM shows near complete inhibition of p4E-BP1 T37/46 , while inhibition of pS6 S240/244 levels is similar for Rapamycin and RM compounds. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo RMC-6272 markedly reduces kidney tumor burden in Tsc2 +/- A/J mice after four weeks of treatment. Tumor regrowth is assessed two months after treatment cessation, tumor burden is significantly reduced in the RMC-6272 group as compared to the Rapamycin and MLN0128 groups . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid